Jemal, A. et al. Blight statistics, 2009. CA Blight J. Clin. 59, 225–249 (2009).
Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B. & Hauser, R. The bloom economics of float cancer: a absolute appraisal of the appear literature. Pharmacoeconomics 21, 1315–1330 (2003).
Mitra, A. P., Datar, R. H. & Cote, R. J. Atomic pathways in invasive float cancer: new insights into mechanisms, progression, and ambition identification. J. Clin. Oncol. 24, 5552–5564 (2006).
Mitra, A. P. & Cote, R. J. Atomic pathogenesis and affection of float cancer. Annu. Rev. Pathol. 4, 251–285 (2009).
Bryan, R. T. & Wallace, D. M. 'Superficial' float cancer—time to detach pT1 tumours from pTa tumours. BJU Int. 90, 846–852 (2002).
Pasin, E., Josephson, D. Y., Mitra, A. P., Cote, R. J. & Stein, J. P. Apparent float cancer: an amend on etiology, atomic development, classification, and accustomed history. Rev. Urol. 10, 31–43 (2008).
Stein, J. P. et al. Radical cystectomy in the appraisal of invasive float cancer: abiding after-effects in 1,054 patients. J. Clin. Oncol. 19, 666–675 (2001).
Foresman, W. H. & Messing, E. M. Float cancer: accustomed history, bump markers, and aboriginal apprehension strategies. Semin. Surg. Oncol. 13, 299–306 (1997).
Parekh, D. J., Bochner, B. H. & Dalbagni, G. Apparent and muscle-invasive float cancer: attempt of administration for outcomes assessments. J. Clin. Oncol. 24, 5519–5527 (2006).
Wakui, M. & Shiigai, T. Urinary amplitude blight screening through appraisal of urinary red claret corpuscle aggregate distribution. Int. J. Urol. 7, 248–253 (2000).
Grossfeld, G. D. et al. Asymptomatic diminutive hematuria in adults: arbitrary of the AUA best convenance action recommendations. Am. Fam. Physician 63, 1145–1154 (2001).
Messing, E. M., Young, T. B., Hunt, V. B., Wehbie, J. M. & Rust, P. Urinary amplitude cancers begin by homescreening with hematuria dipsticks in advantageous men over 50 years of age. Blight 64, 2361–2367 (1989).
Messing, E. M. et al. Hematuria home screening: echo testing results. J. Urol. 154, 57–61 (1995).
Messing, E. M. et al. Home screening for hematuria: After-effects of a multiclinic study. J. Urol. 148, 289–292 (1992).
Schroeder, G. L. et al. A ancillary by ancillary allegory of assay and biomarkers for float blight detection. J. Urol. 172, 1123–1126 (2004).
Ramakumar, S. et al. Allegory of screening methods in the apprehension of float cancer. J. Urol. 161, 388–394 (1999).
Halling, K. C. et al. A allegory of BTA stat, claret dipstick, telomerase and Vysis UroVysion assays for the apprehension of urothelial blight in urine. J. Urol. 167, 2001–2006 (2002).
Britton, J. P., Dowell, A. C., Whelan, P. & Harris, C. M. A affiliation abstraction of float blight screening by the apprehension of abstruse urinary bleeding. J. Urol. 148, 788–790 (1992).
Messing, E. M. et al. Allegory of float blight aftereffect in men ability hematuria home screening against those with accepted analytic presentations. Urology 45, 387–396 (1995).
Carmack, A. J. & Soloway, M. S. The assay and staging of float cancer: from RBCs to TURs. Urology 67, 3–8 (2006).
Lotan, Y. & Roehrborn, C. G. Acuteness and specificity of frequently accessible float bump markers against cytology: after-effects of a absolute abstract appraisal and meta-analyses. Urology 61, 109–118 (2003).
Wiener, H. G., Vooijs, G. P. & van't Hof-Grootenboer, B. Accurateness of urinary assay in the assay of primary and alternate float cancer. Acta Cytol. 37, 163–169 (1993).
Mitra, A. P., Birkhahn, M., Penson, D. F. & Cote, R. J. Urine biomarkers for the apprehension of urothelial blight [online], (2009).
Cheng, Z. Z. et al. Complement agency H as a brand for apprehension of float cancer. Clin. Chem. 51, 856–863 (2005).
Black, P. C., Brown, G. A. & Dinney, C. P. Atomic markers of urothelial blight and their use in the ecology of apparent urothelial cancer. J. Clin. Oncol. 24, 5528–5535 (2006).
Abd El Gawad, I. A. et al. Comparative abstraction of NMP-22, telomerase, and BTA in the apprehension of float cancer. J. Egypt. Natl Canc. Inst. 17, 193–202 (2005).
Eissa, S. et al. Comparative appraisal of the nuclear cast protein, fibronectin, urinary float blight antigen and voided urine assay in the apprehension of float tumors. J. Urol. 168, 465–469 (2002).
Miyanaga, N. et al. Usefulness of urinary NMP22 to ascertain bump ceremony of apparent float blight afterwards transurethral resection. Int. J. Clin. Oncol. 8, 369–373 (2003).
Ponsky, L. E. et al. Screening and ecology for float cancer: adorning the use of NMP22. J. Urol. 166, 75–78 (2001).
Grossman, H. B. et al. Surveillance for alternate float blight application a point-of-care proteomic assay. JAMA 295, 299–305 (2006).
Lokeshwar, V. B. & Selzer, M. G. Urinary float bump markers. Urol. Oncol. 24, 528–537 (2006).
Lokeshwar, V. B. et al. Urinary hyaluronic acerbic and hyaluronidase: markers for float blight apprehension and appraisal of grade. J. Urol. 163, 348–356 (2000).
Kim, N. W. et al. Specific affiliation of animal telomerase action with abiding beef and cancer. Science 266, 2011–2015 (1994).
Kavaler, E., Landman, J., Chang, Y., Droller, M. J. & Liu, B. C. Audition animal float blight beef in voided urine samples by assaying for the attendance of telomerase activity. Blight 82, 708–714 (1998).
Schmetter, B. S. et al. A multicenter balloon appraisal of the fibrin/fibrinogen abasement articles assay for apprehension and ecology of float cancer. J. Urol. 158, 801–805 (1997).
Topsakal, M., Karadeniz, T., Anac, M., Donmezer, S. & Besisik, A. Assessment of fibrin-fibrinogen abasement articles (Accu-Dx) assay in float blight patients. Eur. Urol. 39, 287–291 (2001).
Mitra, A. P., Datar, R. H. & Cote, R. J. Atomic staging of float cancer. BJU Int. 96, 7–12 (2005).
Mitra, A. P., Lin, H., Cote, R. J. & Datar, R. H. Biomarker profiling for blight diagnosis, cast and ameliorative management. Natl Med. J. India 18, 304–312 (2005).
Mitra, A. P., Lin, H., Datar, R. H. & Cote, R. J. Atomic assay of float cancer: anxiety and analytic implications. Clin. Genitourin. Blight 5, 67–77 (2006).
Mitra, A. P., Birkhahn, M. & Cote, R. J. p53 and retinoblastoma pathways in float cancer. World J. Urol. 25, 563–571 (2007).
Lokeshwar, V. B. et al. Float bump markers above cytology: International Consensus Panel on float bump markers. Urology 66, 35–63 (2005).
Halling, K. C. Vysis® UroVysion for the apprehension of urothelial carcinoma. Expert Rev. Mol. Diagn. 3, 507–519 (2003).
Halling, K. C. et al. A allegory of assay and fluorescence in situ admixture for the apprehension of urothelial carcinoma. J. Urol. 164, 1768–1775 (2000).
Bubendorf, L. et al. Multiprobe FISH for added apprehension of float blight in voided urine specimens and float washings. Am. J. Clin. Pathol. 116, 79–86 (2001).
Sarosdy, M. F. et al. Analytic appraisal of a multi-target beaming in situ admixture appraisal for apprehension of float cancer. J. Urol. 168, 1950–1954 (2002).
Skacel, M. et al. Multitarget fluorescence in situ admixture appraisal detects capricious corpuscle blight in the majority of patients with float blight and aberant or abrogating urine cytology. J. Urol. 169, 2101–2105 (2003).
Feil, G. et al. Accurateness of the ImmunoCyt appraisal in the assay of capricious corpuscle blight of the urinary bladder. Anticancer Res. 23, 963–967 (2003).
Hautmann, S. et al. Immunocyt and the HA-HAase urine tests for the apprehension of float cancer: A side-by-side comparison. Eur. Urol. 46, 466–471 (2004).
Têtu, B., Tiguert, R., Harel, F. & Fradet, Y. ImmunoCyt/uCyt improves the acuteness of urine assay in patients followed for urothelial carcinoma. Mod. Pathol. 18, 83–89 (2005).
Mian, C. et al. The amount of the ImmunoCyt/uCyt assay in the apprehension and aftereffect of blight in situ of the urinary bladder. Anticancer Res. 25, 3641–3644 (2005).
Mian, C. et al. ImmunoCyt: a new apparatus for audition capricious corpuscle blight of the urinary tract. J. Urol. 161, 1486–1489 (1999).
Lodde, M. et al. Apprehension of aerial urinary amplitude capricious corpuscle blight with ImmunoCyt: a basic report. Urology 58, 362–366 (2001).
Pfister, C. et al. ImmunoCyt assay improves the analytic accurateness of urinary cytology: after-effects of a French multicenter study. J. Urol. 169, 921–924 (2003).
Mian, C. et al. uCyt /ImmunoCyt in the apprehension of alternate urothelial carcinoma: an amend on 1991 analyses. Blight 108, 60–65 (2006).
Lodde, M. et al. uCyt test: another to cystoscopy for less-invasive aftereffect of patients with low accident of urothelial carcinoma. Urology 67, 950–954 (2006).
Birkhahn, M., Mitra, A. P. & Cote, R. J. Atomic markers for float cancer: the alley to a multimarker approach. Expert Rev. Anticancer Ther. 7, 1717–1727 (2007).
Vriesema, J. L., Poucki, M. H., Kiemeney, L. A. & Witjes, J. A. Patient assessment of urinary tests against adjustable urethrocystoscopy in aftereffect assay for apparent float cancer: a account analysis. Urology 56, 793–797 (2000).
Surveillance Epidemiology and End After-effects Blight Carbon Fact Sheets—Urinary Float [online], (2009).
US Department of Bloom and Animal Services Agency for Healthcare Research and Quality Screening for Float Blight in Adults [online], (2004).
Ruttenberg, R. & Powers, M. Economics of notification and medical screening for high-risk workers. J. Occup. Med. 28, 757–764 (1986).
US Department of Labor Consumer Price Index Inflation Calculator [online], (2009).
Lotan, Y., Svatek, R. S. & Sagalowsky, A. I. Should we awning for float blight in a high-risk population?: a amount per life-year adored analysis. Blight 107, 982–990 (2006).
Mitra, A. P. & Cote, R. J. Searching for atypical assay and targets: insights from analytic trials. Urol. Oncol. 25, 341–343 (2007).
Madeb, R., Golijanin, D., Knopf, J. & Messing, E. M. Current accompaniment of screening for float cancer. Expert Rev. Anticancer Ther. 7, 981–987 (2007).
Madeb, R. & Messing, E. M. Abiding aftereffect of home dipstick testing for hematuria. World J. Urol. 26, 19–24 (2008).
Lotan, Y. & Shariat, S. F. Impact of accident factors on the achievement of the nuclear cast protein 22 point-of-care assay for float blight detection. BJU Int. 101, 1362–1367 (2008).
Lotan, Y. et al. Float blight screening in a aerial accident asymptomatic citizenry application a point of affliction urine based protein bump marker. J. Urol. 182, 52–57 (2009).
Steiner, H. et al. Aboriginal after-effects of bladder-cancer screening in a high-risk citizenry of abundant smokers. BJU Int. 102, 291–296 (2008).
Kumar, A., Kumar, R. & Gupta, N. P. Allegory of NMP22 BladderChek assay and urine assay for the apprehension of alternate float cancer. Jpn J. Clin. Oncol. 36, 172–175 (2006).
Kibar, Y. et al. Anxiety amount of cytology, nuclear cast protein 22 (NMP22) test, and urinary float blight II (UBC II) assay in aboriginal alternate capricious corpuscle blight of the bladder. Ann. Clin. Lab. Sci. 36, 31–38 (2006).
Mian, C. et al. Multiprobe fluorescence in situ hybridisation: anxiety perspectives in apparent float cancer. J. Clin. Pathol. 59, 984–987 (2006).
May, M. et al. Comparative analytic amount of urine cytology, UBC-ELISA, and fluorescence in situ admixture for apprehension of capricious corpuscle blight of urinary float in accepted analytic practice. Urology 70, 449–453 (2007).
Bergman, J., Reznichek, R. C. & Rajfer, J. Surveillance of patients with float blight application beaming in-situ admixture on float washings. BJU Int. 101, 26–29 (2008).
Raitanen, M. P. The role of BTA carbon assay in aftereffect of patients with float cancer: after-effects from FinnBladder studies. World J. Urol. 26, 45–50 (2008).
Gacci, M. et al. Pre and postoperative quantitative apprehension of bits of cytokeratins 8 and 18 (UBC IRMA) as markers of aboriginal ceremony of apparent float tumor. Arch. Ital. Urol. Androl. 78, 5–10 (2006).
van der Poel, H. G. et al. Quanticyt: karyometric appraisal of float abrasion for patients with apparent float cancer. Urology 48, 357–364 (1996).
Zheng, S. et al. Membrane microfilter accessory for careful capture, electrolysis and genomic appraisal of animal circulating bump cells. J. Chromatogr. A 1162, 154–161 (2007).
Med Surg Report Sheet Templates - Med Surg Report Sheet Templates | Welcome to be able to my personal blog, within this period I will demonstrate about Med Surg Report Sheet Templates .
0 Response to "Med Surg Report Sheet Templates"
Posting Komentar